Mirum Pharmaceuticals (MIRM) said Monday the US Food and Drug Administration has approved a new tablet formulation of Livmarli to treat cholestatic pruritus in patients with Alagille syndrome and Progressive Familial Intrahepatic Cholestatis.
Livmarli tablets are expected to be available through Mirum Access Plus in June, the company said.
Price: 39.56, Change: -0.02, Percent Change: -0.06
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.